Quadrature Capital’s Meridian Bioscience Inc VIVO Stock Holding History

Quadrature Capital’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,421	Closed	-$297K	–	1039
2022 Q1	$297K	Buy	+11,421	New	+$272K	0.01%	519
2021 Q2	–	Sell	-13,058	Closed	-$343K	–	1306
2021 Q1	$343K	Buy	+13,058	New	+$310K	0.02%	585
2020 Q1	–	Sell	-16,585	Closed	-$162K	–	759
2019 Q4	$162K	Sell	16,585 -2,111	-11%	-$19.8K	0.01%	458
2019 Q3	$177K	Sell	18,696 -9,390	-33%	-$99K	0.01%	515
2019 Q2	$334K	Buy	+28,086	New	+$338K	0.02%	352
2019 Q1	–	Sell	-15,554	Closed	-$270K	–	746
2018 Q4	$270K	Buy	+15,554	New	+$265K	0.05%	351
2017 Q2	–	Sell	-20,107	Closed	-$277K	–	834
2017 Q1	$277K	Buy	+20,107	New	+$281K	0.02%	536

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VLKIM

Van Lanschot Kempen Investment Management Amsterdam, Netherlands $11.4B AUM 16.77% 1-Year Est. Return

Quadrature Capital's VIVO Position: Q2 2022 in Review

Quadrature Capital sold out of Meridian Bioscience Inc (VIVO) in Q2 2022, closing a stake of 11,421 shares — an estimated $297K sold.

Quadrature Capital first reported a position in VIVO in Q1 2017 and held it in 7 quarters. The position peaked at $343K in Q1 2021. 216 funds tracked by Wall St. Rank hold VIVO as of Q2 2022.

Quadrature Capital reported no remaining Meridian Bioscience Inc position as of Q2 2022 after selling out during the quarter.
Quadrature Capital sold 11,421 Meridian Bioscience Inc shares in Q2 2022, an estimated $297K.
Quadrature Capital first reported a position in Meridian Bioscience Inc in Q1 2017 and held it in 7 quarters.
Quadrature Capital's Meridian Bioscience Inc position peaked at $343K in Q1 2021.
216 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2022.

Based on Quadrature Capital's 13F filing for Q2 2022, filed 15 Aug 2022.